RPRodion V. Ponomarev

Rodion V. Ponomarev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rodion V. Ponomarev has a total of 231 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Iron accumulation in the heart of a patient with primary hemochromatosis type I (homozygous C282Y mutation of the HFE gene)

    by M.H.E. Laouar, R. V. Ponomarev, M. A. Kanunnikova, E. S. Neronova, N. T. Tynybekova, I. V. Tremzina, M. M. Malagina, A. B. Leonova, V. А. Baranova, E. O. Saakyants, et al.

    Primary hemochromatosis results from pathogenic variants in several genes that can lead to increased iron stores in the body, with excess iron deposited in various organs including the liver, pancreas, and heart. Primary hemochromatosis is associated with homozygosity for the HFE p.Cys282Tyr mutation in 80% of cases. However, rare cases of hemochromatosis (nonHFE hemochromatosis) can be caused by pathogenic variants in other genes (such as HJV, HAMP, TFR2, and SLC40A1). Deposition of excess iron in parenchymal tissues leads to cellular dysfunction and clinical manifestations of the disease. The most commonly aff ected organs are the liver, pancreas, joints, skin, pituitary gland, and heart. Iron-overload cardiomyopathy is systolic or diastolic dysfunction of the heart caused by excess iron deposition, resulting in chronic heart failure. The gold standard for diagnosing primary hemochromatosis is genetic testing, which should be performed in all patients suspected of having this pathology after excluding secondary causes of iron overload. The mainstay of hemochromatosis therapy is therapeutic phlebotomy and iron chelation. The article presents a clinical case of a patient with primary hemochromatosis and a history of very high serum ferritin levels, which led to iron accumulation in the heart.

  • Stress-induced cardiomyopathy (takotsubo syndrome) in a patient with primary hemochromatosis

    by E. V. Reznik, M. H.E. Laouar, R. V. Ponomarev, D. V. Ustyuzhanin, A. D. Belyakova, G. N. Golukhov

    Hemochromatosis is a disease associated with excess iron in the body. Primary (hereditary) hemochromatosis, occurs due to mutations in genes encoding iron metabolism proteins. Elevated serum iron concentrations can lead to iron accumulation in parenchymatous organs and tissues, especially in the liver, pancreas, heart, pituitary gland, and testicles, resulting in the development of fibrosis and failure of these organs. Diagnosis of hereditary hemochromatosis includes genetic testing, evaluation of serum iron metabolism parameters, and imaging data. The article describes a case of Takotsubo syndrome development in a patient with primary hemochromatosis. Takotsubo syndrome is characterized by transient regional systolic dysfunction, dilation and edema of the apical and/or middle segments of the left ventricle (LV), in the absence of coronary artery obstruction during coronary angiography. At the age of 49, an examination revealed an increase in ferritin, genetic testing revealed a homozygous mutation C282Y in the HFE gene, hereditary hemochromatosis was diagnosed, erythrocytapheresis was performed, and she is being monitored by a hematologist. At the age of 56, she was hospitalized with suspected acute coronary syndrome with ST segment elevation, an increase in troponin I levels to 1.8 ng/ml. Coronary angiography did not reveal any hemodynamically significant stenosis. Echocardiography revealed hypoand dyskinesis of the apical segments, a decrease in the LV ejection fraction to 45%. Dynamically, normalization of the troponin level, ECG, and restoration of LV function were noted. Takotsubo syndrome was diagnosed in a patient with primary hemochromatosis, the combination of which was not mentioned in previously published works.

  • Open Access

    Interim results of the first stage of a multicenter open multi-cohort study of the safety, pharmacokinetics, pharmacodynamics and efficacy of veranafusp alfa in adult patients with mucopolysaccharidosis type II

    by E. A. Lukina, R. V. Ponomarev, S. V. Trishina, E. S. Gabitova, N. D. Vashakmadze, G. A. Karkashadze, L. S. Namazova-Baranova

    This article presents the interim results of the first stage (administration of the drug to patients aged ≥18 years with mucopolysaccharidosis type II) of a multicenter open multi-cohort phase II-III study (IDB-MPS-II-III), the aim of which was to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of veranafusp alfa in patients with MPS II. Material and methods. The interim analysis included data from 3 patients aged 18 years and older who had previously received idursulfase (2/3) and idursulfase beta (1/3). An individual dose increase (1–2–3 mg/kg) was performed after 2 weeks, followed by administration at a dose of 3 mg/kg for up to 52 weeks (a total of 52 weekly infusions). Standard PK parameters were evaluated. The PD criterion was the level of glycosaminoglycans (GAGs) in urine, blood and cerebrospinal fluid (CSF). Efficacy parameters included assessment of the dynamics of GAGs concentration in urine, blood and CSF, range of motion in joints, liver and spleen volume, change in the 6-minute walk test (6MWT, 6-minute test), left ventricular myocardial mass, forced vital capacity of the lungs (FVC). Safety parameters included assessment of the frequency of adverse events (AEs) and adverse reactions (ARs), including allergic and infusion reactions, as well as assessment of the frequency of formation of anti-drug antibodies (ADAs) and their neutralizing activity. Results. The studied drug demonstrated non-linear PK in the blood and a dose-dependent increase in concentration in the CSF. Patients showed a decrease or stability in the level of GAG in the urine, a decrease in the level of heparan sulfate (HS) in the CSF in 2 (66.6%) of 3 patients, as well as a decrease in the level of dermatan sulfate (DS) in the CSF in the range of 17.19–80.96%. There was an average decrease in liver volume by 42.500 ± 218.496 cm 3 , spleen volume by 24.350 ± 9.405 cm 3 and left ventricular myocardial mass by 15.333 ± 43.016 g relative to the baseline level. The average increase in walking distance according to the results of the 6MWT, after 1 year of therapy, was 76.067 ± 83.561 m. The average values of FVC and FEV1 did not change statistically significantly. 9 AEs were registered in 3 patients (100.0%) of mild severity, mainly from the liver and biliary tract, and 3 ARs, which were infusion reactions and were registered mainly in the first 4 months of therapy. During the analyzed period, the frequency of formation of ADAs at screening was in 2 patients, and at week 52 — in 3 patients, which indicates the development of de novo ADAs during treatment with veranafusp alfa in 1 patient. Conclusion. Weekly intravenous administration of the drug under study to adult patients at a dose of 3 mg/kg for 1 year provided control of the level of GAG in the urine and stabilization and/or improvement of somatic symptoms according to spirometry, echocardiography, 6MWT, range of motion in large joints, liver and spleen size, comparable to the results of the effectiveness of treatment with idursulfase in patients previously receiving enzyme replacement therapy. There was a tendency to decrease the level of HS in the cerebrospinal fluid, which may indicate the ability of veranafusp alfa to penetrate the BBB and deliver idursulfase to brain tissue, preventing the accumulation of pathological substrate in the CNS to prevent neurodegenerative changes.


  • Open Access

    Prevention of Iron Deficiency and Iron Deficiency Anemia in Various Patient Categories in the Russian Federation. Expert Council Resolution

    by O. M. Drapkina, O. N. Tkacheva, E. V. Shikh, L. Yu. Drozdova, I. I. Baranov, I. G. Bakulin, B. A. Bakirov, R. V. Ponomarev, A. V. Starodubova, T. A. Fedorova, et al.

    At the Expert Council meeting, key issues related to the prevention of latent iron deficiency (LID) and iron deficiency anemia (IDA) in at-risk populations were discussed, including women of reproductive age, pregnant women, blood donors, and patients with chronic diseases. Participants reviewed international and national guidelines, acceptable levels of iron intake, as well as barriers limiting the implementation of standard preventive approaches in clinical practice. Particular attention was given to chelated forms of iron, especially iron bisglycinate, noted for its high bioavailability and favorable tolerability profile. The experts emphasized the importance of using formulations containing components that enhance iron absorption and metabolism. Following the discussion, a resolution was adopted reflecting the consolidated interdisciplinary position of specialists on the prevention of LID and IDA, including patient management algorithms, care pathways, risk group identification, and recommendations for improving the regulatory framework.


  • Open Access

    Prevention of Iron Deficiency and Iron Deficiency Anemia in Various Patient Categories in the Russian Federation. Expert Council Resolution

    by O. M. Drapkina, O. N. Tkacheva, E. V. Shikh, L. Yu. Drozdova, I. I. Baranov, I. G. Bakulin, B. A. Bakirov, R. V. Ponomarev, A. V. Starodubova, T. A. Fedorova, et al.

    At the Expert Council meeting, key issues related to the prevention of latent iron deficiency (LID) and iron deficiency anemia (IDA) in at-risk populations were discussed, including women of reproductive age, pregnant women, blood donors, and patients with chronic diseases. Participants reviewed international and national guidelines, acceptable levels of iron intake, as well as barriers limiting the implementation of standard preventive approaches in clinical practice. Particular attention was given to chelated forms of iron, especially iron bisglycinate, noted for its high bioavailability and favorable tolerability profile. The experts emphasized the importance of using formulations containing components that enhance iron absorption and metabolism. Following the discussion, a resolution was adopted reflecting the consolidated interdisciplinary position of specialists on the prevention of LID and IDA, including patient management algorithms, care pathways, risk group identification, and recommendations for improving the regulatory framework.

  • Open Access

    Management of patients with iron deficiency anemia in the context of primary health care. Guidelines

    by O. M. Drapkina, E. B. Avalueva, I. G. Bakulin, B. А. Bakirov, I. I. Baranov, N. G. Vinogradova, M. A. Vinogradova, T. V. Gaponova, O. V. Gaus, S. R. Gilyarevsky, et al.

    Iron deficiency anemia is a multietiological disease, the development of which is associated with iron deficiency due to its impaired intake, absorption or increased losses, characterized by microcytosis and hypochromic anemia. The practical guide describes in detail the etiology, paraclinical diagnostics, management of patients in various clinical situations. Guidelines are intended for primary health care professionals, including internists, general practitioners, cardiologists, gastroenterologists and other specialists providing care to patients with iron deficiency anemia.


  • Open Access

    Total hip arthroplasty in patients with Gaucher disease: characteristics and outcomes

    by Vasily E. Mamonov, Yulya A. Chabaeva, Vladimir A. Khomenko, Rodion V. Ponomarev, Elena A. Lukina

    BACKGROUND: Avascular necrosis of the femoral head (ANFH) is the indication for total hip arthroplasty (THA) in patients with Gaucher disease (GD). Due to the rarity of GD, the surgical procedure and long-term outcomes in large patient populations have been insufficiently studied. AIM: This study aimed to analyze the perioperative period as well as medium- and long-term outcomes of THA in patients with GD. METHODS: A retrospective, single-center study was conducted in 26 patients with GD who underwent 30 primary THAs and 9 revision hip arthroplasties between 2005 and 2023. RESULTS: Good and excellent THA outcomes were achieved in 87% of cases, with follow-up periods ranging from 1 to 10 years (median: 7 years). Unsatisfactory results during the 10-year follow-up were due to periprosthetic infection (2 cases) and aseptic loosening (3 cases). Both cases of periprosthetic infection were caused by osteoarticular tuberculosis, which was not detected at the prehospital stage. High intraoperative blood loss was associated with the duration of enzyme replacement therapy (ERT). Blood loss of 1000 mL was reported in 57%, 22%, and 0% of surgeries when ERT lasted less than 5 years, 5–10 years, and more than 10 years, respectively (p = 0.047). Implant survival without revision 3, 6, and 12 years post-surgery was 97%, 93%, and 61%, respectively. At 12 years, the survival rates for cemented and uncemented implants without revision were 33% and 67%, respectively. Twelve years post-surgery, implant survival without revision was 43% for the CoCr/PE bearing surface and 83% for other combinations (ceramic/ceramic, ceramic/PE, and modified metal / PE). CONCLUSION: THA improves quality of life in patients with GD after ANFH. Uncemented implants with ceramic-on-ceramic, ceramic-on-polyethylene, or modified metal-on-polyethylene bearings demonstrated greater longevity and lower revision rates. A high risk of perioperative hemorrhagic complications was observed in patients who received ERT for less than 5 years. The risk of periprosthetic infection was 6.7%, and tuberculosis should be ruled out in such cases.


  • Open Access

    Sociomedical Profile and Quality of Life of Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Pathogenetic Therapy

    by T. I. Ionova, A. D. Kulagin, E. A. Lukina, V. V. Ptushkin, E. G. Arshanskaya, T. N. Babaeva, B. A. Bakirov, S. V. Voloshin, G. P. Dimov, O. U. Klimova, et al.

    BACKGROUND. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal non-neoplastic disorder of hematopoietic tissue characterized by complement-mediated hemolysis, bone marrow dysfunction, and higher risk of thrombotic and organic complications. This disease is associated with rapid rate of progression as well as worsening life expectancy and quality of life. Despite high efficacy of anti-complement treatment, a considerable proportion of patients show suboptimal response to pathogenetic therapy. Problems that patients encounter in everyday life, their quality of life, burden of disease, and limitations in professional life have not been adequately addressed in literature. AIM. To study sociomedical profile and quality-of-life indicators of PNH patients with suboptimal response to pathogenetic therapy and to assess the FACIT-Fatigue Scale in terms of its clinical information value and practical significance for analyzing the overall treatment success. MATERIALS & METHODS. As part of the multicenter observational clinical study, PNH patients with suboptimal response to pathogenetic therapy completed the EQ-5D and FACIT-Fatigue questionnaires as well as a checklist of main PNH symptoms, their disease, treatment, and professional life. The method of descriptive statistics as well as the Mann-Whitney test, the χ2 test, and correlation analysis were used to analyze the data. RESULTS. The study was based on the data from 45 PNH patients treated in 12 health centers in Russia (classic PNH accounted for 64.4 %). The age median was 41 years, 62 % of patients were women. The mean duration of suboptimal response to pathogenetic therapy was 3.2 years. Most patients had mobility issues (55.6 %), anxiety/depression (62.2 %), and hardships in their daily activities (68.9 %). In the vast majority of them, the disease had a moderate or considerable impact on their daily activities and social/family life. In 61 % of professionally active patients, the underlying disease moderately or considerably limited their professional life. Most patients reported fatigue (96 %), headache (86 %), dyspnea (83 %), concentration issues and sleep disorders (82 %), rapid heartbeat (77 %), yellowness of the skin (76 %), and back pain (71 %). Pronounced fatigue (with FACIT-Fatigue score of < 40) was registered in 70 % of patients. A significant correlation was established between FACIT-Fatigue and EQ-5D VAS scores as well as a relationship with the severity of dyspnea, tachycardia, and concentration loss. CONCLUSION. This clinical study demonstrated a considerably reduced quality of life of PNH patients with suboptimal response to pathogenetic therapy. It also confirmed the information value of the FACIT-Fatigue Scale for assessing fatigue and its impact on everyday life. This study clearly identified outstanding issues related to PNH patients with suboptimal response to pathogenetic therapy. That can contribute to bringing more patient-oriented care to this challenging population of hematologic patients.


  • Open Access

    Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease

    by E A Lukina, R V Ponomarev, G N Salogub, V A Bezrukikh, E V Saifullina, I L Davydkin, S A Volkova, T V Shelekhova, M V Kosinova, E V Vasiliev, et al.

    Aim. To collect and analyze real-world data on long-term enzyme replacement therapy with Glurazyme® in patients with type I Gaucher disease (GD). Materials and methods. The study included 31 patients with type I GD (21 patients with intact spleen and 10 patients with a history of splenectomy) over 18 years. Efficacy was assessed by the change in hemoglobin level (primary endpoint), platelet count, spleen and liver volumes, prevalence of bone marrow infiltration, and the number of patients with quiet hip disease according to magnetic resonance imaging (secondary endpoints). Safety was assessed by the incidence of treatment-related adverse events and serious adverse events, as well as by the incidence of production of imiglucerase binding and neutralizing antibodies (IgG, IgE). The mean follow-up duration was 54 weeks. Results. The study did not show a statistically significant change in hemoglobin levels, platelet count, or spleen and liver volumes. There was an upward tendency in platelet count in the overall group (p=0.1) and patients after splenectomy (p=0.08). The prevalence of specific bone marrow infiltration and the number of patients with quiet hip disease remained unchanged. During the safety analysis, one adverse reaction, a mild increase in alanine aminotransferase, was reported, which resolved spontaneously by the end of the study. The immunogenicity analysis showed the initial presence of anti-drug antibodies (ADAs) in 5 (16.7%) of the 30 examined patients. At the end of the study, ADAs were detected in only 3 (10%) patients. The detected ADAs had a low titer and no neutralizing activity, and they did not affect the treatment effectiveness. Conclusion. Long-term therapy with the imiglucerase biosimilar was associated with a stable course of GD without progression. It was characterized by a good safety profile and low immunogenicity.


  • Open Access

    Radiological and morphological characteristics of the femoral head osteonecrosis in type I Gaucher disease

    by Vasily E. Mamonov, Anastasia A. Solovyova, Dmitry I. Chebotarev, Rodion V. Ponomarev, Vladislav A. Nakonechny, Elena A. Lukina, Соловьева Анастасия Александровна

    BACKGROUND: Osteonecrosis of the femoral head in Gaucher disease type I is an irreversible bone manifestation of the disease. The cause and mechanisms of osteonecrosis in Gaucher disease are still unknown, and their clinical and radiological characteristics must be taken into account when choosing treatment strategy. AIM: To analyze the radial and morphological changes in the proximal femur after osteonecrosis of the femoral head in type I Gaucher disease. MATERIALS AND METHODS: The study included 251 adult patients with type I Gaucher disease from the Russian National Registry; histological examination of 22 removed femoral bone fragments obtained during total hip replacement in 20 patients with Gaucher disease and 9 in patients of the control group was performed. RESULTS: Aseptic necrosis of the femoral head was found in 30% adults with Gaucher disease, and in 20% patients it was associated with femoral head collapse. Osteosclerosis of the cancellous bone of the metaphysis, enlargement / swelling of the medullary cavity with secondary osteopenia and osteoporosis of the proximal femoral diaphysis often accompanied osteonecrosis of the femoral head, causing technical difficulties during surgery. The histological findings revealed a picture of chronic bone tissue ischaemia of the proximal femoral metaphysis, which was confirmed by the detection of widespread areas of osteosclerosis on radiography and MRI. Bone marrow infiltration by Gaucher cells in histological preparations persisted regardless of the duration of enzyme replacement therapy against the background of preserved regenerative potential of bone tissue. CONCLUSIONS: The features of the radiological, MRI and histological picture should be taken into account when planning and performing orthopaedic surgery for aseptic necrosis of the femoral head in patients with type I Gaucher disease.